These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7514089)

  • 1. Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP).
    Garde SV; Sheth AR; Venkatesan VM; Panchal CJ; Porter AT; Grignon DJ
    Cancer Lett; 1994 Apr; 78(1-3):11-7. PubMed ID: 7514089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines.
    Garde SV; Sheth AR; Porter AT; Pienta KJ
    Cancer Lett; 1993 Jul; 70(3):159-66. PubMed ID: 7689036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in immunohistochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer.
    Grob BM; Schellhammer PF; Brassil DN; Wright GL
    Urology; 1994 Oct; 44(4):525-9. PubMed ID: 7524238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands.
    Abrahamsson PA; Lilja H; Falkmer S; Wadström LB
    Prostate; 1988; 12(1):39-46. PubMed ID: 2450341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased immunoexpression of prostate inhibin peptide in prostatic carcinoma: a study with monoclonal antibody.
    Zhang PJ; Driscoll DL; Lee HK; Nolan C; Velagapudi SR
    Hum Pathol; 1999 Feb; 30(2):168-72. PubMed ID: 10029444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three predominant prostatic proteins.
    Abrahamsson PA; Lilja H
    Andrologia; 1990; 22 Suppl 1():122-31. PubMed ID: 1720287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
    Imasato Y; Xuan JW; Sakai H; Izawa JI; Saito Y; Chin JL; Moussa M
    J Urol; 2000 Nov; 164(5):1819-24. PubMed ID: 11025776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies.
    Hakalahti L; Vihko P; Henttu P; Autio-Harmainen H; Soini Y; Vihko R
    Int J Cancer; 1993 Oct; 55(4):590-7. PubMed ID: 7691762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
    Darson MF; Pacelli A; Roche P; Rittenhouse HG; Wolfert RL; Young CY; Klee GG; Tindall DJ; Bostwick DG
    Urology; 1997 Jun; 49(6):857-62. PubMed ID: 9187691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
    Epstein JI; Egevad L; Humphrey PA; Montironi R;
    Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunohistochemical detection of prostate carcinoma].
    Ma WX; Li W
    Zhonghua Bing Li Xue Za Zhi; 1989 Mar; 18(1):37-9. PubMed ID: 2476252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen as a marker of adenocarcinoma of prostate.
    Kellokumpu-Lehtinen P; Nurmi M; Koskinen P; Irjala K
    Urol Res; 1989; 17(4):245-9. PubMed ID: 2475959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroids inversely affect the biosynthesis and secretion of human prostatic acid phosphatase and prostate-specific antigen in the LNCaP cell line.
    Henttu P; Vihko P
    J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):349-60. PubMed ID: 1373297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal modulation of biosynthesis of prostatic specific antigen, prostate specific acid phosphatase and prostatic inhibin peptide.
    Sheth AR; Garde SV; Mehta MK; Shah MG
    Indian J Exp Biol; 1992 Mar; 30(3):157-61. PubMed ID: 1380948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of residual tumor cells following radical radiation therapy for prostatic adenocarcinoma; immunohistochemical expression of prostate-specific antigen, prostatic acid phosphatase, and cytokeratin 8.
    Ljung G; Norberg M; Holmberg L; Busch C; Nilsson S
    Prostate; 1997 May; 31(2):91-7. PubMed ID: 9140121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NKX3.1 as a marker of prostatic origin in metastatic tumors.
    Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
    Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.
    Csapo Z; Brand K; Walther R; Fokas K
    J Urol; 1988 Nov; 140(5):1032-8. PubMed ID: 2459419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical diagnosis of the metastasizing prostatic carcinoma.
    Steffens J; Friedmann W; Lobeck H
    Eur Urol; 1985; 11(2):91-4. PubMed ID: 2408895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma.
    Berner A; Waere H; Nesland JM; Paus E; Danielsen HE; Fosså SD
    Br J Urol; 1995 Jan; 75(1):26-32. PubMed ID: 7531589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.